IgA Nephropathy Diagnosis via Galactose-Deficient IgA1 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating IgA nephropathy are inadequate, as they fail to effectively identify patients at risk and prevent the progression of the disease, particularly due to the complexity of aberrantly glycosylated IgA1 and its interaction with mesangial cells.
Innovation Solution
Developing methods to isolate IgG and detect its binding to galactose-deficient IgA1, including mutations in the IGH gene, and using specific antibodies or polypeptides to inhibit the binding, thereby diagnosing and treating IgA nephropathy by reducing the formation of nephritogenic immune complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for IgA nephropathy, then the disease progression can be monitored, but the early detection capability is insufficient due to the complexity of aberrantly glycosylated IgA1
Solution Approach 1:
The patent extracts the specific diagnostic target from the complex background by focusing on IgG antibodies that bind to galactose-deficient IgA1. Instead of attempting to detect all aspects of aberrantly glycosylated IgA1 directly, the invention uses IgG binding as a surrogate marker, thereby simplifying the detection process while maintaining diagnostic accuracy for early IgA nephropathy detection
Solution Approach 2:
The patent introduces IgG antibodies as an intermediary substance to detect the presence of aberrantly glycosylated IgA1. The IgG serves as a mediator that specifically binds to galactose-deficient IgA1, allowing indirect detection of the complex glycosylation patterns through a more manageable antibody-antigen interaction
2Reliability
If general treatment methods are applied to IgA nephropathy, then the disease progression can be managed, but the effectiveness is limited due to lack of targeted approach
Solution Approach 1:
The patent applies local quality by targeting specific IgG antibodies that bind to galactose-deficient IgA1 rather than applying general immunosuppressive therapy to all patients. This localized targeting approach focuses treatment on the specific pathogenic mechanism involving IgG-IgA1 immune complexes, thereby improving treatment effectiveness while reducing unnecessary side effects from broad-spectrum therapy
Solution Approach 2:
The patent changes the therapeutic parameter from general immunosuppression to specific inhibition of IgG binding to galactose-deficient IgA1. By altering the target parameter from broad immune system suppression to specific antibody-antigen interaction inhibition, the treatment becomes more adaptable and effective for patients with IgA nephropathy
3Loss of time
If IgG binding to galactose-deficient IgA1 is detected, then early diagnosis is achieved, but the diagnostic process becomes more complex
Solution Approach 1:
The patent employs preliminary action by pre-selecting and validating specific IgG antibodies that bind to galactose-deficient IgA1 as diagnostic markers. These pre-identified antibodies can be used directly in diagnostic assays, eliminating the need for complex analytical development during patient evaluation and enabling rapid early diagnosis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable early detection of IgA nephropathy and potential treatment by reducing the risk of disease progression through specific antibody binding inhibition, providing a targeted approach to managing the condition.
Implementation Method 1
determining whether the IgG binds to a galactose-deficient IgA1. Binding of the IgG to the galactose-deficient IgA1 indicates the subject has or is at risk for developing IgA nephropathy
Data Source
AI summary
Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.